Abstract | BACKGROUND: METHODS: The present study focuses on the involvement of heparanase in autoimmunity, applying the murine non-obese diabetic (NOD) model, a T-cell-dependent disease often used to investigate the pathophysiology of type 1 diabetes. RESULTS: It was found that intra-peritoneal administration of heparanase ameliorated the clinical signs of the disease. In vitro studies revealed that heparanase has an inhibitory effect on the activation of T-cells through modulation of their repertoire of cytokines indicated by a marked increase in the levels of IL-4 and IL-10, and a parallel decrease in IL-12, tumour necrosis factor-alpha ( TNF-alpha) and interferon-gamma (IFN-gamma). CONCLUSIONS: We suggest that heparanase induces a shift from a Th1- to Th2-phenotype, resulting in inhibition of diabetes in NOD mice and possibly other autoimmune disorders.
|
Authors | Menachem Bitan, Lola Weiss, Michael Zeira, Shoshana Reich, Orit Pappo, Israel Vlodavsky, Shimon Slavin |
Journal | Diabetes/metabolism research and reviews
(Diabetes Metab Res Rev)
2008 Jul-Aug
Vol. 24
Issue 5
Pg. 413-21
ISSN: 1520-7552 [Print] England |
PMID | 18561210
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Cytokines
- Tumor Necrosis Factor-alpha
- Interleukin-10
- Interleukin-12
- Interleukin-4
- Interferon-gamma
- heparanase
- Glucuronidase
|
Topics |
- Animals
- Cytokines
(biosynthesis)
- Diabetes Mellitus, Type 1
(prevention & control)
- Female
- Glucuronidase
(pharmacology)
- Humans
- Interferon-gamma
(biosynthesis)
- Interleukin-10
(biosynthesis)
- Interleukin-12
(biosynthesis)
- Interleukin-4
(biosynthesis)
- Lymphocyte Activation
(drug effects)
- Mice
- Mice, Inbred NOD
- Th1 Cells
(physiology)
- Th2 Cells
(physiology)
- Tumor Necrosis Factor-alpha
|